1. Could We Eat Our Favorite Fried Foods Without Worrying About Bad Cholesterol?
This week at the J.P. Morgan Healthcare Conference, Verve Therapeutics, a private gene-editing company, presented interesting pre-clinical data on coronary heart disease (CHD) in non-human primates. In the U.S., CHD is the leading cause of death, one every 36 seconds.
Verve’s scientists discovered that by inactivating the PCSK9 gene they were able to lower the level of low-density lipoprotein (LDL), or bad cholesterol, and therefore the probability of heart attacks in non-human primates that otherwise seemed healthy.
Gene-editing potentially could inactivate the PCSK9 gene permanently. Specifically, int
Verve presented data showing that one treatment of in vivo base editing to inactivate the
In our opinion, this encouraging data suggests
2. Could Most Electric Vehicle (EV) Startups Go Bankrupt?
Outside of China, the number of EV companies going public is mounting and, if automotive history is any guide, we believe most will disappear in one way or another. As gas-
3. In A Lackluster Year For Sports, Online Betting Took Off
Despite shortened seasons, canceled tournaments, and low viewershi
While sports betting in various formats is legal in 21 states and Washington DC, online sports betting accounts for most of the incremental growth. Only 15 states and Washington DC have legalized ‘online’ sports betting, but we believe it is burgeoning thanks to its convenience and entertainment
Augmenting fantasy sports and e-sports, legalized online sports betting is giving companies – and the
4. Invitae And PacBio Are Partnering To Design An Ultra-High-Throughput DNA Sequencing Platform
During the J.P. Morgan Healthcare Conference last week, Invitae (NVTA), a leading medical genetics company, and Pacific Biosciences “PacBio” (PACB), a provider of long-read sequencing instruments, announced a colla
Bolstered not only by results from this year’s PrecisionFDA Truth Challenge but also by improvements in HiFi accuracy via Google’s (GOOGL) DeepVariant as well as research community feedback, we think PacBio’s HiFi sequencing method provides the most complete and accurate view of the human genome.
To drive widespread adoption, PacBio likely needs to improve instrument throughput and variable cost. Collaborating with Invitae, we imagine PacBio can gain critical insights into its customers’ challenges, from automated sample prep to large-scale data processing. Invitae’s high sample volume could help PacBio’s long-read sequencing to capitalize on its Wright’s Law curve, as costs decline 28% for every cumulative doubling in the number of whole human genomes sequenced on long-read machines.
In our opinion, HiFi sequencing should help Invitae pull furth
Ultimately, we believe the